6-amino-3-(2-methylpropyl)-1,3-dihydropyrimidine-2,4-dione | 59341-76-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-amino-3-(2-methylpropyl)-1,3-dihydropyrimidine-2,4-dione
• 英文别名: 6-amino-3-(2-methylpropyl)-1H-pyrimidine-2,4-dione
• CAS: 59341-76-3
• 化学式: C₈H₁₃N₃O₂
• 分子量: 183.21
• InChiKey: HULCQAAULJKYCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-amino-3-(2-methylpropyl)-1,3-dihydropyrimidine-2,4-dione 在 溶剂黄146 、 sodium nitrite 作用下， 反应 1.0h， 生成 6-amino-5-nitroso-3-(2-methylpropyl)-1,3-dihydropyrimidine-2,4-dione
  参考文献：
  名称：

  Selective, high affinity A2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

  摘要：

  A series of N-1 monosubstituted 8-pyrazolyl xanthines have been synthesized and evaluated for their affinity for the adenosine receptors (AdoRs). We have discovered two compounds 18 (CVT-7124) and 28 (CVT-6694) that display good affinity for the A(2B) AdoR (K-i = 6 nM and 7 nM, respectively) and greater selectivity for the human A(1), A(2A), and A(3) AdoRs (> 1000-, > 830-, and > 1500-fold; > 850-, > 700-, and > 1280- fold, respectively). CVT-6694 has been shown to block the release of interleukin-6 and monocyte chemotactic protein-1 from bronchial smooth muscle cells (BSMC), a process believed to be promoted by activation of A2B AdoR. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.008
• 作为产物：
  描述：

  4-氨基-2,6-二羟基嘧啶 、 溴代异丁烷 在 硫酸氢铵 、 六甲基二硅氮烷 作用下， 生成 6-amino-3-(2-methylpropyl)-1,3-dihydropyrimidine-2,4-dione
  参考文献：
  名称：

  Selective, high affinity A2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

  摘要：

  A series of N-1 monosubstituted 8-pyrazolyl xanthines have been synthesized and evaluated for their affinity for the adenosine receptors (AdoRs). We have discovered two compounds 18 (CVT-7124) and 28 (CVT-6694) that display good affinity for the A(2B) AdoR (K-i = 6 nM and 7 nM, respectively) and greater selectivity for the human A(1), A(2A), and A(3) AdoRs (> 1000-, > 830-, and > 1500-fold; > 850-, > 700-, and > 1280- fold, respectively). CVT-6694 has been shown to block the release of interleukin-6 and monocyte chemotactic protein-1 from bronchial smooth muscle cells (BSMC), a process believed to be promoted by activation of A2B AdoR. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.008

文献信息

• Method of wound healing using A2B adenosine receptor antagonists
  申请人：Zeng Dewan

  公开号：US20060058322A1

  公开（公告）日：2006-03-16

  The present invention relates to methods of wound healing using A 2B adenosine receptor antagonists. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

  本发明涉及使用A2B腺苷受体拮抗剂进行伤口愈合的方法。该发明还涉及制备此类化合物的方法，以及包含它们的药物组合物。
• A2B adenosine receptor antagonists
  申请人：——

  公开号：US20040176399A1

  公开（公告）日：2004-09-09

  Disclosed are processes for the synthesis of novel compounds that are A 2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  披露的是合成新型化合物的过程，这些化合物是A2B腺苷受体拮抗剂，可用于治疗包括哮喘和腹泻在内的各种疾病状态。
• METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Zeng Dewan

  公开号：US20070219221A1

  公开（公告）日：2007-09-20

  The invention is related to methods of preventing and treating hepatic fibrosis using A 2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.

  本发明涉及使用A2B腺苷受体拮抗剂预防和治疗肝纤维化的方法，以及在治疗和预防因酒精滥用、外科手术干预、病毒性肝炎、摄入肝毒性药物或其他肝脏疾病引起的肝脏损伤中的用途。本发明还涉及用于该方法的药物组合物。
• [EN] XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE XANTHINE SERVANT D'ANTAGONISTES DU RECEPTEUR DE L'ADENOSINE A2B
  申请人：CV THERAPEUTICS INC

  公开号：WO2004106337A1

  公开（公告）日：2004-12-09

  Disclosed are compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  揭示了一种A2B腺苷受体拮抗剂化合物，可用于治疗包括哮喘和腹泻在内的各种疾病状态。
• A2B Adenosine receptor antagonists
  申请人：Kalla Rao

  公开号：US20050261316A1

  公开（公告）日：2005-11-24

  Disclosed are novel compounds that are A 2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  揭示了一种新颖的化合物，它们是A2B腺苷受体拮抗剂，可用于治疗包括哮喘和腹泻在内的各种疾病状态。